VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

ASH 2014 | ASH 2014: Phase II SPRINT study of lenalidomide in relapsed/refractory mantle cell lymphoma

Marek Trněný • 5 Dec 2015
ASH 2014
Mantle Cell Lymphoma Lenalidomide
SPRINT

Prof Marek Trněný (Charles University Hospital, Prague, Czech Republic) at the 2014 American Society of Hematology (ASH) Annual Meeting discusses the phase 2 SPRINT (MCL-002) study of lenalidomide versus investigator’s choice in relapsed or refractory mantle cell lymphoma, including the study design, efficacy and safety endpoints, and conclusions

More from Marek Trněný

2:28
Improving outcomes for R/R DLBCL with polatuzumab vedotin
Marek Trněný • 14 Jun 2018
3:38
Results of Phase III GADOLIN trial for follicular lymphoma
Marek Trněný • 3 Jun 2016
3:03
Progress in mantle cell lymphoma over the last 15 years
Marek Trněný • 23 Sep 2016
2:17
Treating mantle cell lymphoma earlier in the disease course
Marek Trněný • 12 Jun 2015

Related Videos

3:01
Treating indolent and mantle cell lymphoma: results of the BRIGHT 5 year follow up study
Ian Flinn
1:07
MCL trials to watch out for at ASH 2019
Simon Rule
1:33
Developing mantle cell lymphoma treatment for further success
John Kuruvilla
1:15
Clinical impact of ATM and TP53 mutations in mantle cell lymphoma
Jitka Malčíková
VJHemOnc VJHemOnc is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter

Subscribe now
The content of VJHemOnc is intended for healthcare professionals